Shareholder Return Plan: QIAGEN announced plans to return approximately $500 million to shareholders through a synthetic share repurchase, enhancing shareholder confidence and improving the company's image after returning about $650 million in 2024.
Exceeding Commitment: The anticipated completion of this repurchase in January 2026 will enable QIAGEN to fulfill its commitment to return at least $1 billion to shareholders by 2028 ahead of schedule, showcasing the company's strong cash flow and financial health.
Capital Structure Optimization: This repurchase is expected to reduce the number of issued shares by approximately 5%, enhancing earnings per share (EPS) and potentially boosting stock performance, thereby attracting more investors.
Shareholder Meeting Support: The annual general meeting in June 2025 overwhelmingly approved the repurchase plan, reflecting strong shareholder endorsement of the company's strategy and further solidifying management's decision-making authority.
QGEN
$44.96+Infinity%1D
Analyst Views on QGEN
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
Wall Street analysts forecast QGEN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QGEN is 49.34 USD with a low forecast of 45.00 USD and a high forecast of 55.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 45.210
Low
45.00
Averages
49.34
High
55.00
Current: 45.210
Low
45.00
Averages
49.34
High
55.00
Morgan Stanley
Equal Weight
maintain
2025-12-15
New
Reason
Morgan Stanley
Price Target
2025-12-15
New
maintain
Equal Weight
Reason
Morgan Stanley raised the firm's price target on Qiagen to EUR 42 from EUR 41 and keeps an Equal Weight rating on the shares.
Barclays
NULL
to
Overweight
maintain
$53 -> $55
2025-12-15
New
Reason
Barclays
Price Target
$53 -> $55
2025-12-15
New
maintain
NULL
to
Overweight
Reason
Barclays raised the firm's price target on Qiagen to $55 from $53 and keeps an Overweight rating on the shares. The firm adjusted ratings and price targets in the life sciences and diagnostics tools space as part of its 2026 outlook. The last of the estimate cuts, recovering end markets and tools being the "most under-owned space in healthcare" creates a "great setup" for outperformance of the tools group in 2026, the analyst tells investors in a research note.
Citi
Patrick Donnelly
Buy -> Neutral
downgrade
$55 -> $50
2025-12-11
Reason
Citi
Patrick Donnelly
Price Target
$55 -> $50
2025-12-11
downgrade
Buy -> Neutral
Reason
Citi analyst Patrick Donnelly downgraded Qiagen to Neutral from Buy with a price target of $50, down from $55. The firm adjusted ratings in the life science tools and diagnostics group as part of its 2026 outlook. It sees Qiagen shares remaining in a trading range given its challenging comparisons and margin dilution from recent acquisitions.
Berenberg
Harry Gillis
Buy
downgrade
2025-11-12
Reason
Berenberg
Harry Gillis
Price Target
2025-11-12
downgrade
Buy
Reason
Berenberg analyst Harry Gillis lowered the firm's price target on Qiagen to EUR 46 from EUR 50 and keeps a Buy rating on the shares.
About QGEN
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
